INTRODUCTION: The measurement of body composition such as the skeletal muscle index (SMI) has been reported to be useful for predicting prognosis in hepatocellular carcinoma (HCC). In this study, we analyzed skeletal muscle change during sorafenib and lenvatinib therapy and the association between SMI and prognosis. METHODS: A total of 67 patients with advanced HCC and Child-Pugh grade A status treated with tyrosine kinase inhibitors (TKIs) at Hiroshima University between September 2009 and December 2018 were enrolled in this retrospective cohort study. Patients underwent computed tomography (CT) imaging before starting sorafenib treatment and 1-3 months after treatment initiation. RESULTS: In all patients, the median SMI was 45.3 cm<sup>2</sup>/m<sup>2</sup> before TKI treatment and 42.1 cm<sup>2</sup>/m<sup>2</sup> after treatment; 54 of 67 (80.6%) patients experienced SMI loss. The median ΔSMI was -1.5 cm<sup>2</sup>/m<sup>2</sup>/months, and no difference in ΔSMI was observed between patients receiving sorafenib and lenvatinib. No significant differences were observed in median ΔSMI between patients with and without progressive disease (-2.35 and -1.1 cm<sup>2</sup>/m<sup>2</sup>/months, respectively), albumin-bilirubin grade 1 and 2 group disease (-1.7 and -1.5 cm<sup>2</sup>/m<sup>2</sup>/months, respectively), and relative dose intensity ≤80 and >80 (-1.8 and -1.2 cm<sup>2</sup>/m<sup>2</sup>/months, respectively). CONCLUSION: This report demonstrated that patients receiving TKI treatment experienced a significant loss of skeletal muscle mass regardless of disease progression, hepatic reserve, or which TKI (sorafenib or lenvatinib) they received.
INTRODUCTION: The measurement of body composition such as the skeletal muscle index (SMI) has been reported to be useful for predicting prognosis in hepatocellular carcinoma (HCC). In this study, we analyzed skeletal muscle change during sorafenib and lenvatinib therapy and the association between SMI and prognosis. METHODS: A total of 67 patients with advanced HCC and Child-Pugh grade A status treated with tyrosine kinase inhibitors (TKIs) at Hiroshima University between September 2009 and December 2018 were enrolled in this retrospective cohort study. Patients underwent computed tomography (CT) imaging before starting sorafenib treatment and 1-3 months after treatment initiation. RESULTS: In all patients, the median SMI was 45.3 cm<sup>2</sup>/m<sup>2</sup> before TKI treatment and 42.1 cm<sup>2</sup>/m<sup>2</sup> after treatment; 54 of 67 (80.6%) patients experienced SMI loss. The median ΔSMI was -1.5 cm<sup>2</sup>/m<sup>2</sup>/months, and no difference in ΔSMI was observed between patients receiving sorafenib and lenvatinib. No significant differences were observed in median ΔSMI between patients with and without progressive disease (-2.35 and -1.1 cm<sup>2</sup>/m<sup>2</sup>/months, respectively), albumin-bilirubin grade 1 and 2 group disease (-1.7 and -1.5 cm<sup>2</sup>/m<sup>2</sup>/months, respectively), and relative dose intensity ≤80 and >80 (-1.8 and -1.2 cm<sup>2</sup>/m<sup>2</sup>/months, respectively). CONCLUSION: This report demonstrated that patients receiving TKI treatment experienced a significant loss of skeletal muscle mass regardless of disease progression, hepatic reserve, or which TKI (sorafenib or lenvatinib) they received.
Authors: Yong S Chang; Jalila Adnane; Pamela A Trail; Joan Levy; Arris Henderson; Dahai Xue; Elizabeth Bortolon; Marina Ichetovkin; Charles Chen; Angela McNabola; Dean Wilkie; Christopher A Carter; Ian C A Taylor; Mark Lynch; Scott Wilhelm Journal: Cancer Chemother Pharmacol Date: 2006-12-08 Impact factor: 3.333
Authors: Lisa Martin; Laura Birdsell; Neil Macdonald; Tony Reiman; M Thomas Clandinin; Linda J McCargar; Rachel Murphy; Sunita Ghosh; Michael B Sawyer; Vickie E Baracos Journal: J Clin Oncol Date: 2013-03-25 Impact factor: 44.544
Authors: Carla M M Prado; Jessica R Lieffers; Linda J McCargar; Tony Reiman; Michael B Sawyer; Lisa Martin; Vickie E Baracos Journal: Lancet Oncol Date: 2008-06-06 Impact factor: 41.316
Authors: Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail Journal: Cancer Res Date: 2004-10-01 Impact factor: 13.312